

Rosai-Dorfman Disease Market - 2022-2030

<https://marketpublishers.com/r/R5EAE3B0AF49EN.html>

Date: December 2025

Pages: 243

Price: US\$ 2,999.00 (Single User License)

ID: R5EAE3B0AF49EN

Abstracts

The Rosai-Dorfman Disease Market was valued at US\$ 405.0 million in 2022 and is anticipated to reach US\$ 667.5 million by 2030, at a CAGR of 0.066 from 2026 to 2032.

The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the Rosai-Dorfman Disease Market.

This report delivers a comprehensive overview of the Rosai-Dorfman Disease Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Rosai-Dorfman Disease Market. The Rosai-Dorfman Disease Market size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for 2022–2030.

Rosai-Dorfman Disease Market Scope:

By Type

Classic (nodal) Rosai-Dorfman disease

Extranodal Rosai-Dorfman disease

By Age Group

Children

Adults

By Procedure Type

Diagnosis

Treatment

By End User

Hospitals

Diagnostic centers

Cancer centers

Key Players

Koninklijke Philips N.V.

GE HealthCare

Canon Inc

Siemens Healthineers

SternMed GmbH

Jubilant Cadista Pharmaceuticals Inc

LGM Pharma

Henan Lihua Pharmaceutical Co., Ltd

Niksan Pharmaceutical

Sandoz Canada Inc

Major Highlights

This report delivers a comprehensive overview of the Rosai-Dorfman Disease Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Rosai-Dorfman Disease Market. The Rosai-Dorfman Disease Market size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for 2022–2030.

This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

Regional Analysis:

North America (U.S., Canada, Mexico)

Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

South America (Colombia, Brazil, Argentina, Rest of South America)

Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Partner Identification

Increase Your Customer Base by 3X using our Partner Identification tool

Uncover strategic collaboration opportunities with DataM vetted partners aligned to your ecosystem.

Identify high potential M&A targets based on synergies, market positioning and growth trajectory.

Prioritize partners by strategic fit rather than general capability.

Why Choose DataM?

Data-Driven Insights: Dive into detailed analyses with granular insights such as pricing, market shares and value chain evaluations, enriched by interviews with industry leaders and disruptors.

Post-Purchase Support and Expert Analyst Consultations: As a valued client, gain direct access to our expert analysts for personalized advice and strategic guidance, tailored to your specific needs and challenges.

White Papers and Case Studies: Benefit quarterly from our in-depth studies related to your purchased titles, tailored to refine your operational and marketing strategies for maximum impact.

Annual Updates on Purchased Reports: As an existing customer, enjoy the privilege of annual updates to your reports, ensuring you stay abreast of the latest market insights and technological advancements. Terms and conditions apply.

Specialized Focus on Emerging Markets: DataM differentiates itself by delivering in-depth, specialized insights specifically for emerging markets, rather than offering generalized geographic overviews. This approach equips our clients with a nuanced understanding and actionable intelligence that are essential for navigating and succeeding in high-growth regions.

Value of DataM Reports: Our reports offer specialized insights tailored to the latest trends and specific business inquiries. This personalized approach provides a deeper, strategic perspective, ensuring you receive the precise

information necessary to make informed decisions. These insights complement and go beyond what is typically available in generic databases.

Target Audience 2026

Manufacturers/ Buyers

Industry Investors/Investment Bankers

Research Professionals

Emerging Companies

Contents

1. METHODOLOGY AND SCOPE

- 1.1. Research Methodology
- 1.2. Research Objective and Scope of the Report

2. DEFINITION AND OVERVIEW

3. EXECUTIVE SUMMARY

- 3.1. Snippet by Type
- 3.2. Snippet by Age Group
- 3.3. Snippet by Procedure Type
- 3.4. Snippet by End User
- 3.5. Snippet by Region

4. DYNAMICS

- 4.1. Impacting Factors
 - 4.1.1. Drivers
 - 4.1.1.1. The rise of FDA Approvals
 - 4.1.1.2. Raising awareness of Rosai-Dorfman Disease
- 4.2. Restraints
 - 4.2.1. Limited Treatment Options for the Rosai-Dorfman Disease
 - 4.2.1. Opportunity
 - 4.2.2. Impact Analysis

5. INDUSTRY ANALYSIS

- 5.1. Porter's Five Force Analysis
- 5.2. Supply Chain Analysis
- 5.3. Pricing Analysis
- 5.4. Regulatory Analysis
- 5.5. Russia-Ukraine War Impact Analysis
- 5.6. DMI Opinion

6. COVID-19 ANALYSIS

- 6.1. Analysis of COVID-19
 - 6.1.1. Scenario Before COVID
 - 6.1.2. Scenario During COVID
 - 6.1.3. Scenario Post COVID
- 6.2. Pricing Dynamics Amid COVID-19
- 6.3. Demand-Supply Spectrum
- 6.4. Government Initiatives Related to the Market During Pandemic
- 6.5. Manufacturers Strategic Initiatives
- 6.6. Conclusion

7. BY TYPE

- 7.1. Introduction
 - 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
 - 7.1.2. Market Attractiveness Index, By Type
- 7.2. Classic (nodal) Rosai-Dorfman disease*
 - 7.2.1. Introduction
 - 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 7.3. Extranodal Rosai-Dorfman disease

8. BY AGE GROUP

- 8.1. Introduction
 - 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), ByAge Group
 - 8.1.2. Market Attractiveness Index, By Age Group
- 8.2. Children*
 - 8.2.1. Introduction
 - 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 8.3. Adults

9. BY PROCEDURE TYPE

- 9.1. Introduction
 - 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Procedure Type
 - 9.1.2. Market Attractiveness Index, By Procedure Type
- 9.2. *Diagnosis
 - 9.2.1. Introduction
 - 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
 - 9.2.3. Imaging procedures

- 9.2.3.1. MRI
- 9.2.3.2. CT scan
- 9.2.3.3. Nuclear medicine
- 9.2.4. Blood tests
- 9.2.5. Biopsy
- 9.2.6. Surgery
- 9.3. Treatment
 - 9.3.1. Radiation therapy
 - 9.3.2. Chemotherapy
 - 9.3.3. Corticosteroids
 - 9.3.4. Immunotherapy

10. BY END USER

- 10.1. Introduction
 - 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
 - 10.1.2. Market Attractiveness Index, By End User
- 10.2. Hospitals*
 - 10.2.1. Introduction
 - 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 10.3. Diagnostic centers
- 10.4. Cancer centers

11. BY REGION

- 11.1. Introduction
 - 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
 - 11.1.2. Market Attractiveness Index, By Region
- 11.2. North America
 - 11.2.1. Introduction
 - 11.2.2. Key Region-Specific Dynamics
 - 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
 - 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
 - 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Procedure Type
 - 11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
 - 11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
 - 11.2.7.1. U.S.
 - 11.2.7.2. Canada
 - 11.2.7.3. Mexico

11.3. Europe

11.3.1. Introduction

11.3.2. Key Region-Specific Dynamics

11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type

11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group

11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Procedure Type

11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

11.3.7.1. Germany

11.3.7.2. UK

11.3.7.3. France

11.3.7.4. Italy

11.3.7.5. Spain

11.3.7.6. Rest of Europe

11.4. South America

11.4.1. Introduction

11.4.2. Key Region-Specific Dynamics

11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type

11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group

11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Procedure Type

11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

11.4.7.1. Brazil

11.4.7.2. Argentina

11.4.7.3. Rest of South America

11.5. Asia-Pacific

11.5.1. Introduction

11.5.2. Key Region-Specific Dynamics

11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type

11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group

11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Procedure Type

11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

11.5.7.1. China

11.5.7.2. India

11.5.7.3. Japan

11.5.7.4. Australia

11.5.7.5. Rest of Asia-Pacific

11.6. Middle East and Africa

- 11.6.1. Introduction
- 11.6.2. Key Region-Specific Dynamics
- 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
- 11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Procedure Type
- 11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

12. COMPETITIVE LANDSCAPE

- 12.1. Competitive Scenario
- 12.2. Market Positioning/Share Analysis
- 12.3. Mergers and Acquisitions Analysis

13. COMPANY PROFILES

- 13.1. Koninklijke Philips N.V.*
 - 13.1.1. Company Overview
 - 13.1.2. Product Portfolio and Description
 - 13.1.3. Financial Overview
 - 13.1.4. Key Developments
- 13.2. GE HealthCare
- 13.3. Canon Inc
- 13.4. Siemens Healthineers
- 13.5. SternMed GmbH
- 13.6. Jubilant Cadista Pharmaceuticals Inc
- 13.7. LGM Pharma
- 13.8. Henan Lihua Pharmaceutical Co., Ltd
- 13.9. Nixsan Pharmaceutical
- 13.10. Sandoz Canada Inc (*LIST NOT EXHAUSTIVE)

14. APPENDIX

- 14.1. About Us and Services
- 14.2. Contact Us

I would like to order

Product name: Rosai-Dorfman Disease Market - 2022-2030

Product link: <https://marketpublishers.com/r/R5EAE3B0AF49EN.html>

Price: US\$ 2,999.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/R5EAE3B0AF49EN.html>